Reconsidering the evidence for CTO PCI: the devil is in the detail

EuroIntervention 2023;19:537-538. DOI: 10.4244/EIJ-E-23-00040

Rasha Al-Lamee
Rasha K. Al-Lamee1, PhD; Sarosh A. Khan2,3, MBBS; John Davies2,3, PhD
1. National Heart and Lung Institute, Imperial College London, London, UK; 2. Essex Cardiothoracic Centre, Basildon, Essex, UK; 3. Anglia Ruskin University, Chelmsford, Essex, UK
Over the last two decades, there has been an explosion in the number of percutaneous chronic total occlusion (CTO) procedures performed worldwide, with high success rates and a greater emphasis on education and training1. Despite technological advancements and the implementation of revascularisation algorithms, it is important to note that the evidence base supporting CTO revascularisation remains limited, primarily consisting of observational data from dedicated registries with only a handful of unblinded randomised controlled trials2345.

In this issue of EuroIntervention, Werner et al present the 3-year safety endpoints from a trial to Evaluate the Utilization of Revascularization ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Transcatheter aortic valve implantation: the shape matters

Latest news